Search results
Psoriasis: Features That May Affect Biologic Rx Outcomes
Medscape· 2 days agoSeveral clinical characteristics were negatively associated with responses to biologics in a...
Certain Clinical Factors Tied to Poor Response to Biologics for Psoriasis
MedPage Today· 2 days agoPrevious exposure to biologics, higher BMI, smoking all negatively linked to response
Psoriasis study shows high level of arthritis symptoms in patients
Medical Xpress· 2 days agoThe study led by researchers at the Universities of Oxford, University College Dublin and supported...
IgG4-Related Disease Affects Men More Often, More Severely
Medscape· 6 hours agoA recent study highlighted sex-based differences in manifestations of IgG4-related disease.
The Gut-Skin Axis May Be the Key to Healthy, Glowing Skin
First for Women via Yahoo News· 7 days agoWhether we’re talking about brain fog, weight loss or the immune system, lately it seems it all...
Hongkongers told to safeguard against ‘flesh-eating’ bacteria when in Japan
South China Morning Post· 4 days agoAn infection of the “flesh-eating” bacteria Streptococcus pyogenes, or Group A streptococcus, can...
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis
Zacks via Yahoo Finance· 22 hours agoThe studies also achieved a key secondary endpoint of endoscopic improvement. Skyrizi is already...
Amgen Inc. (NASDAQ:AMGN) Given Average Recommendation of “Moderate Buy” by Analysts
ETF DAILY NEWS· 9 hours agoAmgen Inc. (NASDAQ:AMGN – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twenty-one brokerages that are presently covering the stock, Marketbeat Ratings ...
In a 'gold rush' for treating bowel disease, AbbVie clears one more stage
Crain s Chicago Business· 16 hours agoWith the arrival of biosimilar competition for its blockbuster drug Humira, AbbVie has said much of its sales growth potential lies with these two anti-inflammatories. In April, the North Chicago ...
FDA Approves Skyrizi for Ulcerative Colitis
Medscape· 1 day agoThe approval is the fourth indication for the anti–interleukin 23 monoclonal antibody after approval for Crohn's disease, psoriatic arthritis, and plaque...